Ryan J. Sullivan
Dana-Farber Cancer Institute(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, Immunotherapy and Immune Responses, CAR-T cell therapy research, Immune cells in cancer
Most-Cited Works
- → Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq(2016)5,064 cited
- → Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma(2018)1,980 cited
- → Myocarditis in Patients Treated With Immune Checkpoint Inhibitors(2018)1,482 cited
- → A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade(2018)1,406 cited
- → EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis(2016)1,214 cited
- → Resistance to checkpoint blockade therapy through inactivation of antigen presentation(2017)979 cited
- → BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma(2013)936 cited
- → Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma(2021)828 cited
- → Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab(2016)814 cited
- → Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma(2018)805 cited